Progress in the therapeutic applications of siRNAs against HIV-1.
Therapeutic options against the human immunodeficiency virus type 1 (HIV-1) continue to expand with the development of new drugs and new therapeutic strategies. Nevertheless, management of HIV-1 infected individuals has become increasingly complex. The emergence of drug-resistant variants, the growing recognition of the long-term toxicity of antiretroviral therapies and the persistence of viral reservoirs justify the continued efforts to develop new anti-HIV-1 strategies. Recent advances regarding the utility of RNA-mediated interference (RNAi) to specifically inhibit HIV-1 replication have opened new possibilities for the development of gene-based therapies against HIV-1 infection. Here, the recent advances in siRNA-based therapies are reviewed.
Martínez
Miguel Angel
MA
Fundacio irsiCaixa, Universitat Autònoma de Barcelona, Spain.
D015658:HIV Infections / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics / Q000627:therapeutic use*; D014779:Virus Replication / Q000235:genetics*
D034741:RNA, Small Interfering